Search
Sirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigational[A242372] In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. … [L39267] Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis.
Products: LIKMUN-E, RAPAMUNE 1 MG 100 FILM DRAJEDurvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigational[A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage … [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in
Products: IMFINZI 500 MG/10 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET, IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/MLSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalIn addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. … On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).
Products: SUNITINIB EG, Sutent Capsule 25 mgInfluenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB14414ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Flulaval 2010/2011Synonyms: Influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (UV, formaldehyde inactivated)Moxonidine
go.drugbank.com/drugs/DB09242ApprovedInvestigationalWithdrawnIt is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. … As well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome.
Products: MOXONIDINA EG, Normohex 0,2 mg - FilmtablettenRizatriptan
go.drugbank.com/drugs/DB00953ApprovedInvestigational[L46018] Used in the treatment of migraines, rizatriptan was first approved in the US in 1998. … [L46018] Rizatriptan is available in oral tablets, orally disintegrating tablets (wafers), and oral film formulations.
Synonyms: N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine, N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamineProducts: RIZATRIPTAN EG, RIZATRIPTAN LIN 1A PHA 5MGPromethazine
go.drugbank.com/drugs/DB01069ApprovedInvestigationalPromethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946.
Mixtures: ARTU 100 ML SURUP, COPHADYL-E COUGH LINCTUSSynonyms: N,N,α-trimethyl-10H-phenothiazine-10-ethanamine, N,N,alpha-trimethyl-10H-phenothiazine-10-ethanamineLevocarnitine
go.drugbank.com/drugs/DB00583ApprovedInvestigationalIt is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.
Synonyms: 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner saltProducts: METACARTİN 100 MG/ML ŞURUP, 100 ML, CARNITENE % 30 ORAL SOLUSYON, 20 MLAlpha-1-proteinase inhibitor
go.drugbank.com/drugs/DB00058ApprovedInvestigationalHuman alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.
Synonyms: Alpha-1 MP, Wap four-disulfide core domain protein 4Products: PROLASTIN C 1000 MG IV İNFÜZYON İÇİN LİYOFİLİZE TOZ İÇEREN FLAKON, 1 ADET, Prolastin 1000 mg - Pulver und Lösungsmittel zur Herstellung einer InfusionslösungSIG-007
go.drugbank.com/drugs/DB17710ExperimentalSIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A.